Bernhard Witzenbichler.

Assuming a 7.5 percent rate of the safety end point of major adverse cardiovascular events in both stent groups, we calculated that the study would have 80 percent power to display the noninferiority of paclitaxel-eluting stents in comparison with bare-metal stents for the principal safety end point. Data were analyzed according to the combined group assignment, of the treatment received regardless. Categorical outcomes were compared by means of the chi-square test or Fisher’s exact check.Rock, B.A., Eric R. Olson, Ph.D., Claudia L.D., Preston W. Campbell, M.D., Melissa A. Ashlock, M.D., and Bonnie W. Ramsey, M.D.: Aftereffect of VX-770 in Persons with Cystic Fibrosis and the G551D-CFTR Mutation Cystic fibrosis can be a progressive lung disease1 caused by mutations in the gene encoding the cystic fibrosis transmembrane conductance regulator protein, an epithelial ion channel involved in fluid and salt transportation in multiple organs, like the lung.